Bio-Synthesis Inc. Introduces "BNA-NC" - A Third Generation Multi Functional Bridged Nucleic Acid

Bio-Synthesis is proud to announce that it has acquired a license from BNA Inc. of Osaka, Japan for the manufacturing and distribution of BNA-NC, a third generation of BNA oligonucleotides. This agreement is valid worldwide and is meant for research use only at this time  (Patents JP: 4731324(2011.4.28), USP: 7427672(2008.9.23), EP: 1551905(2012.4.25)).

In 1997, the first generation BNA (2'-O ,4'-C-methylene-bridged nucleic acid, 2',4'-BNA, also known as LNA) was developed by Prof. Takeshi Imanishi of Osaka University (now, Emeritus Professor and CEO of BNA Inc.) and co-workers. This was followed by development of second generation BNAs such as 2',4'-BNA-COC, 5'-amino-2',4'-BNA.

The third generation of 2',4'-BNA-NC contains a 6-membered ring with a N-O bond between the 2'-hydroxyl and the 4'-carbon of the ribose moiety. It exhibits very strong binding affinity to complementary single stranded RNA, DNA, and double stranded DNA with a highly sequence-selective mode. In particular, the binding ability to complementary RNA is significantly high. BNA-NC also possesses great stability due to its nuclease resistant properties. (Follow the full Press Release here.)